Industry insiders have hinted at it. Analysts have alluded to it. Some experts may claim even to have predicted it. Now they’re finally proclaiming it: There’s no longer room in the market for pure-play SNP-genotyping instrument or services companies.
If you’re thinking about getting into the market you should reconsider. And if you’re a one-time SNP-only play and have courted other markets, congratulations, the clock on your company’s future has begun to tick more quickly.